BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Life Sciences PA - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Life Sciences PA
X-ORIGINAL-URL:https://lifesciencespa.org
X-WR-CALDESC:Events for Life Sciences PA
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260908T100000
DTEND;TZID=America/New_York:20260908T110000
DTSTAMP:20260831T153902Z
CREATED:20260831T153851Z
LAST-MODIFIED:20260831T153902Z
UID:321743-1788861600-1788865200@lifesciencespa.org
SUMMARY:Live Webinar: Improve Drug Solubility from Formulation to Scale-Up
DESCRIPTION:Poor drug solubility continues to be one of the most significant challenges in small molecule drug development\, impacting bioavailability\, formulation design\, clinical performance\, timelines and overall development risk. With an estimated 80-90% of molecules currently in development exhibiting poor solubility characteristics\, sponsors are increasingly seeking integrated strategies that can accelerate decision-making while reducing the risk of costly reformulation and scale-up challenges. \nIn this webinar\, expert speakers will explore how a connected development strategy can help sponsors successfully navigate solubility challenges from early development through clinical supply. The session will examine how understanding a molecule’s physicochemical properties and biopharmaceutic profile\, coupled with a flexible clinical development plan and objectives\, can guide the selection and optimization of the most appropriate formulation approach and enabling technology. \nAttendees will gain insight into the key considerations for selecting between approaches such as hot melt extrusion (HME)\, spray dried dispersions (SDD)\, lipid-based formulations and particle size reduction technologies\, while also learning how early formulation decisions can influence future scale-up\, manufacturing robustness\, regulatory strategy and commercial readiness. \nThe webinar will cover amorphous solid dispersion development considerations\, including stable ASD development through HME and spray drying pathways. It will also examine how scalable development strategies can support formulation continuity from first-in-human studies through later-stage clinical development. Real-world examples will illustrate how integrated development models can help accelerate formulation optimization\, generate clinically relevant data earlier and support informed decisions throughout the product lifecycle. \nThe session will provide practical guidance for evaluating formulation options\, planning clinical supply and developing a fit-for-purpose strategy that balances scientific\, clinical and commercial considerations. \nRegister for this webinar to learn how drug solubility strategies can reduce formulation and scale-up risk throughout small molecule development. \n			\n				Click Here to Register
URL:https://lifesciencespa.org/event/live-webinar-improve-drug-solubility-from-formulation-to-scale-up/
CATEGORIES:Supported Events
END:VEVENT
END:VCALENDAR